<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology of heart failure with preserved ejection fraction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology of heart failure with preserved ejection fraction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology of heart failure with preserved ejection fraction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry A Borlaug, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Heart failure (HF) can be defined as the inability of the heart to provide sufficient forward output to meet the perfusion and oxygenation requirements of the tissues while maintaining normal filling pressures. There are two major cardiac mechanisms by which this can occur.</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic dysfunction, in which there is impaired cardiac contractile function</p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic dysfunction, in which there is abnormal cardiac relaxation, stiffness or filling</p><p></p><p>While it is convenient to consider systolic and diastolic dysfunction as separate processes, the truth is that the two almost always coexist, as they are mechanistically intertwined with one another. The pathophysiology of HF with preserved ejection fraction (HFpEF) will be reviewed here. The clinical manifestations, diagnosis, treatment, and prognosis of HFpEF are discussed separately. (See  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>It is important to define and distinguish several terms when classifying patients with HF.</p><p class="headingAnchor" id="H3"><span class="h2">HFpEF versus HFrEF</span><span class="headingEndMark"> — </span>Patients with chronic HF can be divided into two broad categories (or sometimes three) on the basis of the left ventricular ejection fraction (LVEF). While somewhat arbitrary, patients in these two groups share many key differences on average  (<a class="graphic graphic_figure graphicRef87847" href="/d/graphic/87847.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>]:</p><p>HFpEF is characterized by a normal LVEF, normal LV end-diastolic volume, and abnormal diastolic function, often with LV concentric remodeling or hypertrophy, but sometimes with normal ventricular geometry [<a href="#rid3">3-9</a>]. Most authorities define HFpEF by LVEF ≥50 percent [<a href="#rid10">10,11</a>]. The dominant abnormality resides in diastole, but there are also abnormalities in systolic function, the left atrium, pulmonary vasculature, right ventricle, arteries, and skeletal muscle [<a href="#rid12">12</a>].</p><p>HF with reduced EF (HFrEF) is characterized by more profound abnormalities in systolic function than what are seen in HFpEF, usually with progressive chamber dilation and eccentric remodeling. HFrEF is now most commonly defined by LVEF ≤40 percent [<a href="#rid9">9,10,13</a>].</p><p>Studies have shown that there is a third group of patients with mid-range or mildly reduced LVEF (HFmrEF; 41 to 49 percent) that seem to share features of both HFrEF and HFpEF. While there are few prospective trials in this cohort, some data suggest that the clinical course of these patients is most similar to that of patients with HFrEF [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/3490.html" rel="external">"Approach to diagnosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p>HFrEF and HFpEF are distinct syndromes, not a continuous spectrum of disorders [<a href="#rid9">9</a>]. Distinctions between HFpEF and HFrEF include epidemiologic differences, LV morphologic differences, as well as differences in the cardiomyocytes and extracellular matrix [<a href="#rid9">9,16-20</a>]. Conversion from HFpEF to HFrEF is uncommon and generally associated with an incident injury (such as myocardial infarction) [<a href="#rid21">21-23</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Diastolic dysfunction versus HFpEF</span><span class="headingEndMark"> — </span>Diastolic dysfunction and HFpEF are not synonymous terms [<a href="#rid24">24</a>]. Diastolic dysfunction indicates a functional abnormality of diastolic relaxation, filling, or distensibility of the LV, regardless of whether the LVEF is normal or abnormal and whether the patient is symptomatic or not. Thus, diastolic dysfunction refers to abnormal mechanical properties of the ventricle. HFpEF denotes the signs and symptoms of clinical HF in a patient with a normal LVEF and LV diastolic dysfunction. Diastolic dysfunction alone is essentially part of normal human aging and is seen in many people that do not or never will have HFpEF. However, the presence of diastolic dysfunction is clearly a risk factor for developing HFpEF [<a href="#rid25">25-27</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The approach to the diagnosis of HFpEF is presented separately. (See  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">PHYSIOLOGY OF LEFT VENTRICULAR DIASTOLE</span><span class="headingEndMark"> — </span>An appreciation of normal diastolic function permits a better understanding of the clinical features of HFpEF. Cardiac function is critically dependent upon diastolic physiologic mechanisms to provide adequate LV filling (cardiac input) in parallel with LV ejection (cardiac output). These processes must function under a variety of physiologic conditions, both at rest and during exercise.</p><p>LV diastolic pressure is determined by the volume of blood in the ventricle, the distensibility or compliance of the ventricle, and the degree of external pressure applied on the LV by the pericardium and right heart chambers. During diastole, the LV, left atrium (LA), and pulmonary veins form a "common chamber," which is continuous with the pulmonary capillary bed  (<a class="graphic graphic_figure graphicRef74512" href="/d/graphic/74512.html" rel="external">figure 2</a>). Thus, an increase in LV diastolic pressure will increase pulmonary venous (and capillary) pressure, which can cause dyspnea, exercise limitation, and pulmonary congestion.</p><p class="headingAnchor" id="H8"><span class="h2">Events during diastole</span><span class="headingEndMark"> — </span>Diastole begins with the relaxation of the contracted myocardium. This is a dynamic, energy-dependent process that includes two phases  (<a class="graphic graphic_figure graphicRef61186" href="/d/graphic/61186.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Isovolumic relaxation – Isovolumic relaxation is the period between aortic valve closure and mitral valve opening during which LV pressure declines with no change in volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Auxotonic relaxation – During the period of auxotonic relaxation, the LV fills at variable pressure beginning with mitral valve opening and ending by mid diastole in normal individuals and most patients.</p><p></p><p>During diastole in the normal heart, there is rapid pressure decay associated with "untwisting" and elastic recoil of the LV, producing a suction effect that promotes ventricular filling by increasing the LA-LV pressure gradient and pulling blood into the ventricle. This process is augmented during exercise to compensate for the abbreviated diastolic filling period induced by the associated increase in heart rate. (See <a class="local">'Normal response to exercise'</a> below.)</p><p>During the later phases of diastole, cardiomyocytes are relaxed, and the normal LV is compliant and readily distensible, with minimal resistance to additional LV filling over a normal volume range. Atrial contraction contributes 20 to 30 percent to total LV filling volume, but usually increases diastolic pressures by less than 5 mmHg.</p><p>Normal diastolic properties allow LV filling to be accomplished by very low filling pressures in the LA and pulmonary veins, thereby preserving a low pulmonary capillary hydrostatic pressure (&lt;12 to 15 mmHg) and a high degree of lung distensibility. Loss of normal LV diastolic relaxation and distensibility impairs LV filling, resulting in increases in LV, LA, and pulmonary venous pressures during diastole, which directly increase the pulmonary capillary pressure. Acutely and chronically, these changes may affect gas exchange and contribute to symptoms of dyspnea [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Normal response to exercise</span><span class="headingEndMark"> — </span>Cardiac output can increase several-fold during exercise, an appropriate response to the enhanced needs of exercising muscle for oxygen delivery. Multiple factors contribute to this response, including an increase in heart rate, a modest rise in stroke volume, a reduction in peripheral vascular resistance, and an elevation in LV contractile function [<a href="#rid12">12,29</a>].</p><p>The increase in cardiac output must be matched by an increase in LV input. However, increased input cannot be accomplished by the same mechanisms that increase output. As an example, the rise in heart rate that contributes to increased output also shortens the duration of diastole. To offset this and maintain or increase stroke volume, the diastolic filling rate during exercise must increase to support the increase in cardiac output.</p><p>Increased LV filling requires a rise in the rate of diastolic flow across the mitral valve, which in turn requires an increase in the transmitral diastolic pressure gradient. The normal LV permits a remarkable increase in diastolic filling rate during exercise by rapidly and markedly decreasing LV pressure during early diastole, thereby augmenting the LV "suction" effect and enhancing the transmitral pressure gradient without increasing LA pressure  (<a class="graphic graphic_figure graphicRef51956" href="/d/graphic/51956.html" rel="external">figure 4</a>) [<a href="#rid30">30-33</a>].</p><p>Some of the mechanisms that effect increases in cardiac output and cardiac input during exercise act in concert on systolic and diastolic function:</p><p class="bulletIndent1"><span class="glyph">●</span>Several mechanisms contribute to the enhanced LV diastolic "suction" effect during exercise. Increased contractile function during exercise enhances early diastolic elastic recoil. Thus, greater systolic shortening produces a smaller end-systolic volume, which increases elastic recoil and results in enhanced early diastolic filling [<a href="#rid32">32</a>]. Studies have shown that the ability to enhance diastolic forces that determine suction and relaxation is strongly correlated with the ability to enhance contractile function [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Treppe effect describes a relationship between the heart rate (or frequency of contraction), LV pressure (or systolic force development), and ejection fraction (or shortening) such that in a normal heart, an increase in heart rate is associated with an increase in contractility over a physiologic range of heart rates. This has been called the systolic "force-frequency relationship." The same mechanism governs the relationship between heart rate and diastolic relaxation rate where increased heart rate in a normal heart is associated with an increased relaxation rate, which contributes to the maintenance of normal LV diastolic pressures and pulmonary venous pressure during exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During exercise in a normal individual, the LV utilizes the Frank-Starling mechanism to augment stroke volume. It is the normal distensibility of the LV that allows an increase in end-diastolic volume with minimal change in late diastolic pressure and no significant change in pulmonary venous pressure.</p><p></p><p>In summary, the normal heart during exercise has an elegant balance of physiologic mechanisms to ensure that cardiac input keeps pace with cardiac output, with preservation of a low pulmonary capillary pressure. These mechanisms result in an increase in measured LV distensibility, as manifested by a downward shift of the LV diastolic pressure-volume curve, especially during early diastole  (<a class="graphic graphic_figure graphicRef79248" href="/d/graphic/79248.html" rel="external">figure 5</a>) [<a href="#rid36">36,37</a>]. These mechanisms are impaired in HFpEF [<a href="#rid12">12,38,39</a>].</p><p class="headingAnchor" id="H15"><span class="h1">ABNORMAL CARDIOVASCULAR STRUCTURE AND FUNCTION</span><span class="headingEndMark"> — </span>HFpEF is often associated with remodeling that affects the LV and left atrial (LA) chambers, the right ventricle (RV), the cardiomyocytes, and the extracellular matrix  (<a class="graphic graphic_table graphicRef55386" href="/d/graphic/55386.html" rel="external">table 1</a>). However, a number of patients with unequivocal hemodynamic evidence of HF do not have structural remodeling of the heart, so the absence of structural heart disease does not exclude the diagnosis of HFpEF.</p><p class="headingAnchor" id="H16"><span class="h2">Structural abnormalities</span><span class="headingEndMark"> — </span>The structural remodeling that often occurs in HFpEF differs dramatically from that in HF with reduced EF (HFrEF).</p><p class="headingAnchor" id="H17"><span class="h3">Chamber remodeling</span><span class="headingEndMark"> — </span>Patients with HFpEF often exhibit a concentric pattern of LV remodeling and a hypertrophic process that is characterized by the following features  (<a class="graphic graphic_figure graphicRef87847" href="/d/graphic/87847.html" rel="external">figure 1</a>) [<a href="#rid3">3,6,8,40-45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A normal or near-normal end-diastolic volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased wall thickness and/or LV mass.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased ratio of myocardial mass to cavity volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased relative wall thickness (RWT). The RWT is defined as either 2 x (posterior wall thickness) / (LV diastolic diameter) <strong>or </strong>as (septal wall thickness + posterior wall thickness) / (LV diastolic diameter).</p><p></p><p>However, many patients with HFpEF display normal chamber structure without remodeling, so the absence of concentric remodeling does not exclude HFpEF.</p><p>By contrast, patients with HFrEF typically exhibit a pattern of eccentric remodeling with an increase in end-diastolic volume, an increase in LV mass but little increase in wall thickness, and a substantial decrease in the ratio of mass to volume and thickness to radius.</p><p class="headingAnchor" id="H18"><span class="h3">Cardiomyocyte and extracellular matrix remodeling</span><span class="headingEndMark"> — </span>Alterations in organ morphology and geometry are generally paralleled by differences at the microscopic level. In HFpEF, studies to date show that the cardiomyocyte exhibits an increased diameter with little or no change in cardiomyocyte length, corresponding to the increase in LV wall thickness with no change in LV volume. By contrast, in HFrEF, the cardiomyocytes are elongated with little or no change in diameter, corresponding to the increase in LV volume with no change in LV wall thickness.</p><p>In HFpEF, there is sometimes an increase in the amount of collagen with a corresponding increment in the width and continuity of the fibrillar components of the extracellular matrix [<a href="#rid3">3,41,42,46</a>]. While there is typically more interstitial fibrosis in HFpEF than healthy controls, the differences are not invariably striking, and many patients may not show marked evidence of fibrosis [<a href="#rid47">47</a>]. In contrast, HFrEF has been associated with degradation and disruption of the fibrillar collagen, at least early in its development [<a href="#rid3">3,41,42</a>]. In end-stage HFrEF, replacement fibrosis and regional ischemic scarring may result in an overall increase in fibrillar collagen within the extracellular matrix.</p><p class="headingAnchor" id="H19"><span class="h2">Diastolic dysfunction in HFpEF</span><span class="headingEndMark"> — </span>In HFpEF, abnormalities in diastolic function form a major pathophysiologic basis for the development of the clinical syndrome of HF [<a href="#rid4">4-8,41,42,48,49</a>].</p><p class="headingAnchor" id="H3558649830"><span class="h3">Overview of alterations</span><span class="headingEndMark"> — </span>The major abnormalities in LV diastolic function are:</p><p class="bulletIndent1"><span class="glyph">●</span>Slowed, delayed, and incomplete myocardial relaxation</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired rate and extent of LV filling</p><p class="bulletIndent1"><span class="glyph">●</span>Shift of filling from early to late diastole</p><p class="bulletIndent1"><span class="glyph">●</span>Increased dependence on LV filling from atrial contraction</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased early diastolic suction/recoil</p><p class="bulletIndent1"><span class="glyph">●</span>Increased LA pressure during the early filling</p><p class="bulletIndent1"><span class="glyph">●</span>Increased passive stiffness and decreased distensibility of the LV</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced ability to augment relaxation during exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Limited ability to utilize the Frank-Starling mechanism during exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Increased diastolic LV, LA, pulmonary venous pressure at rest and/or during exercise</p><p></p><p>In a given patient, impairment in one or more of these parameters will result in decreased LV chamber distensibility and an increase in diastolic pressure at any given LV volume. When myocardial relaxation is impaired, the rate and amount of early diastolic LV filling are reduced. This reduction requires a relative shift of LV filling to the later part of diastole, with atrial contraction making a more important contribution to ventricular filling than in normal subjects. The redistribution of filling from early to late diastole makes patients with diastolic dysfunction more sensitive than normal individuals to the effects of tachycardia and loss of atrial contraction, such as occurs with atrial fibrillation. An increase in heart rate shortens the duration of diastole and truncates the important late phase of diastolic filling.</p><p class="headingAnchor" id="H1524208463"><span class="h3">Assessment of diastolic dysfunction</span><span class="headingEndMark"> — </span>Clinically, diastolic dysfunction is commonly assessed noninvasively by echocardiography. Cardiac catheterization is reserved for cases of suspected HFpEF with indeterminate findings on noninvasive evaluation. Invasive assessment with a high-fidelity micromanometer at rest and during exercise provides the most comprehensive evaluation. Clinical assessment of diastolic dysfunction is discussed separately. (See  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p>Changes in both afterload (aortic impedance) and diastolic load (LA diastolic pressure) can affect measurements of diastolic function. These load-dependent changes do not reflect alteration in intrinsic relaxation properties. Thus, no index of relaxation can be considered an index of "intrinsic" relaxation rate unless loading conditions and other modulators are held constant or are at least specified.</p><p class="headingAnchor" id="H183098758"><span class="h4">Rate of isovolumic relaxation</span><span class="headingEndMark"> — </span>The rate of LV pressure decline, or the rate of isovolumic relaxation, reflects early diastolic function. Accurate assessment requires a high-fidelity micromanometer catheter. Measures of this property include  (<a class="graphic graphic_figure graphicRef69433" href="/d/graphic/69433.html" rel="external">figure 6</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Peak (-) dP/dt – Peak negative dP/dt is the peak instantaneous rate of LV pressure decline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tau (τ) – Tau is the time constant of isovolumic LV pressure decay [<a href="#rid50">50</a>]. When the natural log of LV diastolic pressure is plotted versus time, Tau is the slope of this linear relationship. Stated in more conceptual terms, Tau is the time required for LV pressure to fall by approximately two-thirds of its initial value.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isovolumic relaxation time (IVRT) – IVRT can be measured with noninvasive echocardiographic techniques.</p><p></p><p>When the relaxation rate is decreased (ie, abnormal diastolic function), Tau is prolonged and the absolute value of the peak negative dP/dt is reduced. IVRT increases with impaired relaxation but then decreases with progressive worsening of diastolic function.</p><p class="headingAnchor" id="H4244881469"><span class="h4">Rate and extent of LV filling</span><span class="headingEndMark"> — </span>The normal LV has a characteristic pattern of filling and transmitral inflow velocities. These indices are most commonly assessed using echocardiography and are discussed separately. (See  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a>.)</p><p class="headingAnchor" id="H2872795112"><span class="h4">Passive elastic stiffness properties</span><span class="headingEndMark"> — </span>LV diastolic stiffness and distensibility are quantified by the position and shape of the LV diastolic pressure-volume (P-V) relationship displayed as a plot of LV pressure and volume throughout diastole  (<a class="graphic graphic_figure graphicRef68133" href="/d/graphic/68133.html" rel="external">figure 7</a>). A relatively stiff, nondistensible ventricle will require higher pressures to achieve a given volume. Thus, an increase in LV diastolic chamber stiffness (or decrease in distensibility) shifts the diastolic P-V curve upwards, and often also increases its slope. (See  <a class="medical medical_review" href="/d/html/3506.html" rel="external">"Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling"</a>.)</p><p>Defining the entire LV filling curve throughout diastole requires the simultaneous measurement of diastolic pressure and volume. This can be done either throughout a single cardiac cycle (to define the diastolic pressure versus volume relationship) or by measuring the end-diastolic pressure-volume coordinate over a series of variably loaded cardiac cycles (to define the end-diastolic pressure versus volume relationship).</p><p>Volume measurements can be made by angiography, echocardiography, or radionuclide imaging techniques. Simultaneous measurements of LV diastolic pressure are usually made invasively. Alternatively, noninvasive Doppler echocardiographic techniques can be used to estimate pulmonary capillary wedge pressure (PCWP). However, echocardiographic estimation of PCWP is subject to limitations, including commonly providing indeterminate results.</p><p class="headingAnchor" id="H19796955"><span class="h4">Exacerbation of diastolic dysfunction during exercise</span><span class="headingEndMark"> — </span>Abnormalities in diastolic function become exaggerated during exercise [<a href="#rid12">12,29,34,38,39</a>]. As noted above, complex changes in diastolic properties are required to increase LV filling in parallel with LV output during periods of exercise. (See <a class="local">'Normal response to exercise'</a> above.)</p><p>Increased heart rates and cardiac output during exercise require more rapid LV filling. Normally, this is accomplished by accelerated LV relaxation, which lowers LV diastolic pressures and increases the LA-LV pressure gradient. Patients with diastolic dysfunction are not able to increase the rate of LV relaxation as necessary to lower LV diastolic pressure and allow more rapid early diastolic filling [<a href="#rid34">34</a>]. Instead, early diastolic filling is increased by an elevation in LA pressure. The increase in LA pressure may result in pulmonary congestion with exercise, a hallmark of HFpEF  (<a class="graphic graphic_figure graphicRef51956" href="/d/graphic/51956.html" rel="external">figure 4</a>) [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2975548329"><span class="h3">Decompensated HFpEF</span><span class="headingEndMark"> — </span>Abnormal LV diastolic function is a common underlying finding in patients with HFpEF. Even when clinically compensated, patients with HFpEF have evidence of diastolic dysfunction, with abnormal relaxation, filling, and stiffness and increased diastolic pressures, though in some cases physiologic stressors such as exercise or volume loading are necessary to bring out the abnormalities [<a href="#rid39">39,51</a>]. (See <a class="local">'Assessment of diastolic dysfunction'</a> above.)</p><p>Further changes in diastolic function occur when patients develop decompensated HFpEF [<a href="#rid52">52-55</a>]. Decompensation into overt HF may be associated with further changes in diastolic relaxation and filling patterns that reduce LV distensibility. The LV diastolic pressure volume relationship is shifted upwards and pulmonary congestion and exercise intolerance may ensue. Alternately, decompensation may be triggered by increases in intravascular volume. These volume-dependent increases in LV diastolic pressure occur along an already steep diastolic pressure-volume curve, and may induce pulmonary congestion without a change in the position or shape of the diastolic pressure-volume curve. Studies have demonstrated that slow and progressive increases in LV diastolic filling pressures often occur over days to weeks preceding any changes in symptoms of signs of HF  (<a class="graphic graphic_figure graphicRef51124" href="/d/graphic/51124.html" rel="external">figure 8</a>) [<a href="#rid45">45,54</a>]. Thus, during the transition from compensated to decompensated HFpEF, pathophysiologic changes in diastolic pressure often occur well in advance of the development of clinical symptoms. Because the clinical manifestations of decompensated HF occur late in this transition process and with apparent rapid onset of symptoms, the term "acute" is often added to the term "decompensated HF." However, while the symptoms of decompensation present acutely, the pathophysiologic processes that underlie the transition from compensated to decompensated HF may not always occur acutely.</p><p>Decompensated HFpEF may be caused by both cardiovascular and noncardiovascular factors (or "triggers"). Such triggers act on preexisting structural and functional abnormalities to precipitate the development of acute decompensated HF. As examples, atrial fibrillation, tachycardia, or uncontrolled hypertension can lead to rapid increases in LA pressures. The abrupt rise in LA pressure causes a significant change in transmitral Doppler flow pattern, and may result in "pseudonormalization." (See  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults", section on 'Mitral inflow velocities and isovolumic relaxation time'</a>.)</p><p>Potential triggers for decompensated HFpEF include [<a href="#rid40">40,56-63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled hypertension and/or noncompliance with antihypertensive therapies</p><p class="bulletIndent1"><span class="glyph">●</span>Increased salt and water intake and/or noncompliance with diuretic use</p><p class="bulletIndent1"><span class="glyph">●</span>Tachyarrhythmias, particularly new onset atrial fibrillation</p><p class="bulletIndent1"><span class="glyph">●</span>Ischemia</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening renal function </p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic lung disease</p><p class="bulletIndent1"><span class="glyph">●</span>Infection</p><p></p><p>These comorbidities act upon the substrate to precipitate acute decompensated HFpEF. Some patients with decompensated HFpEF present with marked hypervolemia and require days of aggressive diuresis. In contrast, some patients have near-normal fluid volume and simply require more optimal control of venous and arterial vascular tone with vasodilators [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H782154429"><span class="h2">Nondiastolic mechanisms in HFpEF</span><span class="headingEndMark"> — </span>Studies have shown that nondiastolic and noncardiac mechanisms also play an important role in the pathophysiology of HFpEF.</p><p class="headingAnchor" id="H22"><span class="h3">Left ventricular systolic function in HFpEF</span><span class="headingEndMark"> — </span>By definition, the LVEF is normal or nearly normal in patients with HFpEF  (<a class="graphic graphic_table graphicRef55386" href="/d/graphic/55386.html" rel="external">table 1</a>). However, EF is a poor and nonspecific index of contractile function. Studies evaluating load-independent measures of chamber and myocardial contractile function have shown that there are decreases in systolic function in patients with HFpEF compared with age matched healthy controls as well as asymptomatic hypertensives [<a href="#rid64">64</a>].</p><p>This finding of impaired systolic function has been confirmed in numerous studies utilizing tissue Doppler and strain imaging techniques [<a href="#rid3">3,65-68</a>]. These abnormalities are most conspicuously noted in longitudinal contraction and motion of the basal LV in the region of the mitral annulus.</p><p>Abnormalities in LV systolic properties are strongly associated with adverse outcome in patients with HFpEF [<a href="#rid64">64,69</a>]. Inability to augment systolic function also begets and worsens diastolic reserve in HFpEF, by limiting elastic recoil and suction effects that normally facilitate filling (see above) [<a href="#rid34">34</a>].</p><p>These relatively mild abnormalities in systolic function at rest become much more significant limitations during exercise, which further stresses an already compromised heart. Prior studies have shown that the inability to augment cardiac output during exercise is largely related to poor systolic reserve, where contractile function cannot be augmented during stress in a normal fashion. This limits the ability to augment forward stroke volume and reduces cardiac output and end-organ perfusion [<a href="#rid34">34,70,71</a>].</p><p class="headingAnchor" id="H471179109"><span class="h3">Pulmonary hypertension and right ventricular dysfunction</span><span class="headingEndMark"> — </span>Roughly 70 to 80 percent of patients with HFpEF display pulmonary hypertension (PH) [<a href="#rid72">72,73</a>]. As left atrial and pulmonary venous pressures increase due to diastolic dysfunction, this increases the pulmonary artery pressure through passive back-transmission of this hydrostatic pressure. With more advanced stages of HFpEF, there may also be changes in pulmonary vascular structure and function leading to a "precapillary" component where pulmonary vascular resistance increases [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"</a>.)</p><p>The presence of PH in HFpEF is associated with adverse outcomes, including increased mortality and HF hospitalization rates [<a href="#rid72">72,73</a>]. Reducing pulmonary artery pressures through diuretic use (which reduces LV and left atrial pressures) decreases HF hospitalizations in HFpEF [<a href="#rid75">75,76</a>], but other trials testing PH-specific therapies in HFpEF have failed to show a convincing benefit [<a href="#rid77">77-79</a>]. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p>Studies have also demonstrated that right ventricular (RV) dysfunction is common in HFpEF, seen in 20 to 35 percent of patients [<a href="#rid73">73,80-82</a>]. Similar to what is seen in the left side of the heart, there is also RV diastolic and systolic dysfunction in HFpEF [<a href="#rid80">80</a>], at least in the more advanced stages of the disease. RV dysfunction seems to develop more in patients with lower LVEF, with more severe PH, and in patients with atrial fibrillation. The presence of RV dysfunction is a potent marker of increased morbidity and mortality, independent of the severity of PH in HFpEF [<a href="#rid83">83-85</a>].</p><p>In a longitudinal study, among 238 patients with HFpEF and normal RV function at the initial examination, 55 (23 percent) developed RV dysfunction during a median follow-up of 4.0 years (interquartile range 2.1–6.1) [<a href="#rid86">86</a>]. Deterioration in RV function was much greater than that seen in the LV over time. The development of RV dysfunction in HFpEF was associated with both prevalent and incident atrial fibrillation (AF), higher body weight, the presence of coronary disease, higher pulmonary artery and LV filling pressures, and RV dilation. Patients with HFpEF developing incident RV dilation had nearly two-fold increased risk of death (adjusted hazard ratio 1.89, 95% CI 1.01 to 3.44) [<a href="#rid86">86</a>]. Therefore, among patients with normal LVEF and significant RV dysfunction, an advanced stage of HFpEF should be suspected.</p><p class="headingAnchor" id="H1563450940"><span class="h3">Endothelial and vascular dysfunction in HFpEF</span><span class="headingEndMark"> — </span>Obesity, insulin resistance, hypertension, and aging are frequently observed comorbidities in HFpEF that are believed to play an important role in the pathophysiology. One common thread that binds these comorbid conditions together and may explain many of the findings in HFpEF is endothelial dysfunction [<a href="#rid19">19,87</a>]. Endothelium-dependent vasodilation is impaired in HFpEF, and the presence and severity of endothelial dysfunction is associated with more severe HF symptoms, worse exercise capacity, and higher event rates [<a href="#rid70">70,88</a>].</p><p>Coronary microvascular dysfunction is common in HFpEF, seen in up to 75 percent of patients [<a href="#rid89">89</a>]. Abnormalities in coronary flow reserve are related to elevations in plasma natriuretic peptide levels [<a href="#rid90">90</a>], and patients with HFpEF commonly display evidence of cardiomyocyte injury during exercise, which may be related to myocardial ischemia [<a href="#rid91">91</a>]. Patients with abnormal coronary microvascular function were shown to be at increased risk for developing HFpEF in long term follow-up, further emphasizing the mechanistic importance for microvascular dysfunction [<a href="#rid92">92</a>].</p><p>People with HFpEF frequently display increased arterial stiffness and reduced central aortic compliance [<a href="#rid93">93</a>]. This increases the lability of blood pressure swings in HFpEF with changes in fluid volume or vasodilator medicine use [<a href="#rid94">94,95</a>]. Patients with greater arterial stiffening display greater elevation in LV filling pressures and more depressed cardiac output reserve during exercise [<a href="#rid96">96</a>]. As such, management of blood pressure can be very challenging in HFpEF, with patients oscillating between severe uncontrolled hypertension and hypotension from day to day.</p><p>In order to accommodate an increase in blood flow to exercising muscle groups during exercise, vasodilation, and reduction in mean vascular resistance occurs. Prior studies have shown that this vasodilatory response to exercise is also impaired in HFpEF compared with control populations [<a href="#rid34">34,70,96,97</a>].</p><p class="headingAnchor" id="H3414956908"><span class="h3">Chronotropic incompetence</span><span class="headingEndMark"> — </span>Chronotropic incompetence is extremely common in HFpEF, with reported prevalence of 57 to 77 percent [<a href="#rid70">70,77</a>]. Cardiac output is equal to the product of stroke volume and heart rate, and the inability to augment heart rate with exercise, together with the known impairment in stroke volume reserve in HFpEF, greatly limits cardiac output responses to exercise in a number of patients [<a href="#rid71">71,97,98</a>]. While chronotropic incompetence is common in HFpEF, there is no evidence at this time that rate adaptive pacing is beneficial in patients with HFpEF.</p><p class="headingAnchor" id="H3201191166"><span class="h3">Abnormalities in the skeletal muscle and periphery</span><span class="headingEndMark"> — </span>Studies have shown that in addition to central (cardiac) limitations, many patients with HFpEF display significant abnormalities that are peripheral in the vasculature (described above) as well as the skeletal muscle, where there may be changes in microvascular density, fat content and distribution, and oxidative metabolism [<a href="#rid99">99-102</a>]. Some of these abnormalities in the skeletal muscle have also been observed in cardiac muscle, suggesting the presence of a systemic process [<a href="#rid47">47,103</a>]. Intriguingly, improvements in physical capacity noted with exercise training appear to be mediated not by the heart, but rather by improvement in these abnormalities that are peripheral to the heart in the muscle and vasculature [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H3999819376"><span class="h3">Atrial fibrillation and left atrial function</span><span class="headingEndMark"> — </span>Atrial fibrillation is very common in people with HFpEF, being noted at some point in roughly two-thirds of patients [<a href="#rid105">105</a>]. The presence of atrial fibrillation is associated with decreased exercise capacity, development and worsening of RV dysfunction (see above), and increased mortality [<a href="#rid80">80,81,105-107</a>]. At this time, prospective data comparing rate and rhythm control strategies in HFpEF are lacking.</p><p>Data indicate that impairments in LA function are also associated with adverse prognosis and greater burden of pulmonary hypertension in patients with HFpEF, even among patients in sinus rhythm without atrial fibrillation [<a href="#rid80">80,81,105,106,108-113</a>].</p><p class="headingAnchor" id="H24"><span class="h1">MECHANISMS BY WHICH CARDIOVASCULAR DISEASES CAUSE HFPEF</span><span class="headingEndMark"> — </span>At this time it remains unclear what processes lead to the cardiac, vascular, and peripheral limitations that cause the clinical syndrome of HFpEF. However, it is clear from epidemiological studies that the leading risk factors for HFpEF are older age, systemic hypertension, obesity, sedentary lifestyle, and myocardial ischemia.</p><p class="headingAnchor" id="H4179594963"><span class="h2">Cardiac senescence</span><span class="headingEndMark"> — </span>Normal aging is associated with many of the same abnormalities that develop in patients with HFpEF, including diastolic dysfunction, loss of systolic and diastolic reserve, vascular stiffening, and chronotropic incompetence. In people with HFpEF, it may be that the cardiac aging process is accelerated [<a href="#rid12">12</a>], and studies suggest that this acceleration is enhanced in women and with weight gain [<a href="#rid25">25,114</a>].</p><p class="headingAnchor" id="H4112906420"><span class="h2">Hypertension, obesity, insulin resistance, and sedentary lifestyle</span><span class="headingEndMark"> — </span>Chronic increases in left ventricular afterload induced by systemic hypertension may lead to concentric remodeling or hypertrophy that predisposes to HFpEF. This may be related to fibrotic changes in the cardiac interstitium or changes in the cardiac myocytes themselves [<a href="#rid1">1</a>]. This form of concentric remodeling in HFpEF was formerly thought to be related to hydraulic stress alone, but studies suggest that comorbid conditions related to obesity and insulin resistance create a proinflammatory milieu that may predispose to ventricular remodeling and stiffening above and beyond what is seen with high blood pressure alone.</p><p>Obesity appears to be a key risk factor and distinct phenotype of HFpEF. Compared with patients without obesity, patients with obesity and HFpEF display greater degrees of volume overload, more right heart dysfunction and remodeling, increased levels of systemic inflammation, poorer exercise capacity, and greater ventricular interdependence with right heart pressure and volume changes influencing the left heart [<a href="#rid115">115,116</a>]. People with obesity and HFpEF have altered venous capacitance, which is associated with increases in diastolic filling pressures [<a href="#rid117">117,118</a>].</p><p>A theoretical framework has been proposed in which comorbidities (such as hypertension, overweight/obese, diabetes mellitus, chronic obstructive pulmonary disease, sedentary lifestyle, and iron deficiency) create a systemic inflammatory state that causes coronary microvascular endothelial dysfunction leading to HFpEF [<a href="#rid87">87,119,120</a>]. A proinflammatory state causes coronary microvascular endothelial cells to produce reactive oxygen species that reduce nitric oxide bioavailability, which in turn decreases protein kinase G activity in cardiomyocytes. Low protein kinase G activity disinhibits cardiomyocyte hypertrophy and results in cardiomyocyte stiffening due to hypophosphorylation of the cytoskeletal protein titin. Coronary microvascular endothelial cells also produce vascular cell adhesion molecule and E-selectin, which promote migration of monocytes into the subendothelium. Transforming growth factor beta released by monocytes stimulates conversion of fibroblasts into myofibroblasts that deposit collagen in the interstitial space.</p><p>Further study is needed to better define the potential role of inflammation and associated alterations in HFpEF and, importantly, to define whether targeting these factors can improve clinical status and outcomes.</p><p class="headingAnchor" id="H3744582407"><span class="h2">Myocardial ischemia</span><span class="headingEndMark"> — </span>Coronary artery disease is very common in HFpEF, seen in up to two-thirds of patients [<a href="#rid23">23,47,121</a>]. The presence of coronary disease in HFpEF is associated with adverse outcome and greater deterioration in left ventricular function with time. The presence or absence of angina and the severity of HF symptoms do not differ in HFpEF patients with or without coronary disease [<a href="#rid23">23</a>].</p><p>Studies have also shown that there may be abnormalities in coronary microvascular function in HFpEF that cause ischemia, even when there is not epicardial coronary stenosis [<a href="#rid89">89-92,121,122</a>]. This may impair oxygen utilization and contribute to diastolic and systolic reserve limitations that develop during exercise [<a href="#rid123">123</a>]. Radiation therapy to the chest has been shown to be a strong risk factor for HFpEF [<a href="#rid124">124</a>]. Cardiac myocytes are not radiosensitive, but endothelial cells are, and this is felt to underlie the increased risk associated with radiation.</p><p>Ischemia can cause a reversible impairment in myocyte systolic properties as well as relaxation and diastolic function. The resultant slowing or failure of myocyte relaxation causes a fraction of actin-myosin crossbridges to persist and continue to generate tension throughout diastole, especially in early diastole, creating a state of "partial persistent systole."</p><p class="headingAnchor" id="H25082686"><span class="h3">Two types of ischemia</span><span class="headingEndMark"> — </span>Ischemia can alter diastolic function by two separate mechanisms: demand ischemia, created by an increase in energy utilization that outstrips the available supply; and supply ischemia, created by a primary decrease in myocardial blood flow.</p><p class="bulletIndent1"><span class="glyph">●</span>Demand ischemia – Demand ischemia typically occurs during exercise or pharmacologically-induced stress. It results from an increase in oxygen demand in the setting of limited coronary flow reserve due to a coronary stenosis and/or ventricular hypertrophy. During demand ischemia, diastolic dysfunction may be related to myocardial adenosine triphosphate (ATP) depletion, a decrease in free energy release from ATP hydrolysis, and a concomitant increase in adenosine diphosphate [<a href="#rid125">125,126</a>], resulting in rigor (rigor bond formation) [<a href="#rid125">125,127</a>]. Although ischemia is also associated with persistence of an increased intracellular calcium concentration during diastole, it is not clear if elevated calcium levels contribute directly to diastolic dysfunction [<a href="#rid128">128</a>]. (See  <a class="medical medical_review" href="/d/html/3451.html" rel="external">"Excitation-contraction coupling in myocardium"</a>.)</p><p></p><p class="bulletIndent1">As a result of rigor, LV pressure decay, as assessed by tau, is impaired and the LV is stiffer than normal during diastole. This will result in retardation of LV filling and increased diastolic pressures [<a href="#rid129">129</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supply ischemia – Supply ischemia results from a marked reduction in coronary flow. The net effect is inadequate coronary perfusion even in the resting state. In experimental models, acute supply ischemia causes an initial transient downward and rightward shift of the diastolic pressure-volume (P-V) curve such that end-diastolic volume increases relative to end-diastolic pressure, indicating a "paradoxical" increase in diastolic compliance [<a href="#rid130">130</a>]. By contrast, during demand ischemia, diastolic compliance falls acutely [<a href="#rid130">130-132</a>].</p><p></p><p>These opposite initial compliance changes with demand and supply ischemia may be explained by differences in the pressure and volume within the coronary vasculature, by the mechanical effects of the normal myocardium adjacent to the ischemic region, and by tissue metabolic factors. The differences between supply and demand ischemia are transient. After more sustained ischemia of 30 to 60 minutes or longer, both types result in decreased diastolic compliance.</p><p class="headingAnchor" id="H26"><span class="h3">Ischemia and pulmonary symptoms</span><span class="headingEndMark"> — </span>Ischemia, either spontaneous or during exercise, prevents the normal increase in left ventricular distensibility and can also cause a rapid and marked increase in left ventricular diastolic chamber stiffness. Left ventricular diastolic pressures quickly increase, resulting in acute pulmonary congestion  (<a class="graphic graphic_figure graphicRef71811" href="/d/graphic/71811.html" rel="external">figure 9</a>). This upward shift of the left ventricular diastolic P-V curve is completely reversible with recovery of myocardial perfusion [<a href="#rid37">37</a>].</p><p>The effects of ischemia explain why many patients with coronary disease have respiratory symptoms with their anginal pain, including wheezing, an inability to take a deep breath, or shortness of breath. Such respiratory symptoms may occur in the absence of anginal pain and are often referred to as "anginal equivalents." (See  <a class="medical medical_review" href="/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a>.)</p><p>These respiratory symptoms are similar to those of HF, which is not surprising since the responsible mechanism is an elevation in pulmonary venous pressure. One study, for example, showed that the acute decrease in LV distensibility and increase in diastolic pressure during angina caused an increase in airway resistance and a reduction in lung compliance [<a href="#rid133">133</a>]. A similar symptom complex may occur in patients with concentric LV hypertrophy during exercise even in the absence of epicardial coronary artery disease.</p><p class="headingAnchor" id="H27"><span class="h3">Reperfusion</span><span class="headingEndMark"> — </span>Ischemic diastolic dysfunction can continue after normal myocardial blood flow has been reestablished (ie, reperfusion). This phenomenon has been noted both after cardiac surgery and after primary reperfusion therapy for an acute myocardial infarction under circumstances of prolonged ischemia (more than 90 to 120 minutes) [<a href="#rid134">134-136</a>].</p><p>Post-ischemic mechanical dysfunction results in both systolic and diastolic dysfunction, and the latter may be a more sensitive parameter of ischemic injury [<a href="#rid130">130</a>]. During reperfusion, left ventricular diastolic chamber stiffness is increased [<a href="#rid134">134,135</a>]. Over time, diastolic dysfunction resolves and it is therefore reasonable to refer to this process as post-ischemic diastolic stunning.</p><p class="headingAnchor" id="H248887929"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86003.html" rel="external">"Patient education: Heart failure with preserved ejection fraction (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13107298"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF) are not synonymous. The term HFpEF is reserved for patients with clinical HF, in the setting of a normal or near-normal left ventricular ejection fraction (LVEF ≥50 percent), and abnormalities in diastolic function. (See <a class="local">'Diastolic dysfunction versus HFpEF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The LVEF functions as the lynchpin for separating the two types of HF. Patients with HFpEF have an LVEF ≥50 percent and usually have normal-sized hearts and often display concentric remodeling or hypertrophy. Patients with HF with reduced ejection fraction (HFrEF) have an LVEF ≤40 percent and display dilated LVs. Patients with HF with mildly reduced LVEF (41 to 49 percent) have some characteristics similar to those with HFrEF and some characteristics similar to those with HFpEF. (See <a class="local">'HFpEF versus HFrEF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During exercise, physiologic mechanisms normally ensure that cardiac input keeps pace with cardiac output with preservation of a low pulmonary venous pressure. (See <a class="local">'Normal response to exercise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most conspicuous and commonly present abnormalities in patients with HFpEF are related to diastolic dysfunction. This may present with impairments in relaxation, increases in chamber stiffness, or both. These abnormalities lead to an increase in LV filling pressures at rest or during exercise that causes dyspnea. (See <a class="local">'Diastolic dysfunction in HFpEF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since both afterload (systolic pressure) and diastolic load (left atrial diastolic pressure) can affect measurement of diastolic function, these factors must be considered in assessing the intrinsic relaxation rate. (See <a class="local">'Assessment of diastolic dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to diastolic dysfunction, patients with HFpEF display systolic dysfunction, limitations in systolic reserve, pulmonary hypertension, right ventricular dysfunction, vascular and endothelial abnormalities, chronotropic incompetence, left atrial dysfunction, and abnormalities in the periphery. The complex interplay of all of these pathophysiologic mechanisms is what drives symptoms and worsens outcome in HFpEF. (See <a class="local">'Nondiastolic mechanisms in HFpEF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Changes in ventricular, vascular, and peripheral structure and function causing HFpEF are believed to be related to aging and comorbid conditions that are commonly seen in HFpEF, including hypertension, obesity, insulin resistance, sedentary lifestyle, and coronary artery disease. This interaction may be mediated by low-grade inflammation, nitrosative stress, loss of nitric oxide availability, and impairments in cellular protein handling. (See <a class="local">'Mechanisms by which cardiovascular diseases cause HFpEF'</a> above.)</p><p></p><p class="headingAnchor" id="H10600308"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Laura Wexler, MD, FACC, FAHA, Michael R Zile, MD, and William H Gaasch, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res 2019; 124:1598.</a></li><li><a class="nounderline abstract_t">Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med 2016; 375:1868.</a></li><li><a class="nounderline abstract_t">Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 2006; 113:296.</a></li><li><a class="nounderline abstract_t">Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104:779.</a></li><li><a class="nounderline abstract_t">Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003; 41:1519.</a></li><li><a class="nounderline abstract_t">Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004; 351:1097.</a></li><li><a class="nounderline abstract_t">Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350:1953.</a></li><li><a class="nounderline abstract_t">Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005; 111:2306.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011; 123:2006.</a></li><li><a class="nounderline abstract_t">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136:e137.</a></li><li><a class="nounderline abstract_t">Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014; 11:507.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.</a></li><li><a class="nounderline abstract_t">Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37:455.</a></li><li><a class="nounderline abstract_t">Borlaug BA. Defining HFpEF: where do we draw the line? Eur Heart J 2016; 37:463.</a></li><li><a class="nounderline abstract_t">Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 2009; 119:3070.</a></li><li><a class="nounderline abstract_t">Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55:526.</a></li><li><a class="nounderline abstract_t">Gaasch WH, Delorey DE, Kueffer FJ, Zile MR. Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol 2009; 104:1413.</a></li><li><a class="nounderline abstract_t">Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 2016; 134:73.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32:670.</a></li><li><a class="nounderline abstract_t">Desai RV, Ahmed MI, Mujib M, et al. Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol 2011; 107:321.</a></li><li><a class="nounderline abstract_t">Rame JE, Ramilo M, Spencer N, et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol 2004; 93:234.</a></li><li><a class="nounderline abstract_t">Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63:2817.</a></li><li><a class="nounderline abstract_t">Zile MR, Baicu CF, Bonnema DD. Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis 2005; 47:307.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Redfield MM, Melenovsky V, et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail 2013; 6:944.</a></li><li><a class="nounderline abstract_t">Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009; 2:105.</a></li><li><a class="nounderline abstract_t">Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011; 306:856.</a></li><li><a class="nounderline abstract_t">Olson TP, Johnson BD, Borlaug BA. Impaired Pulmonary Diffusion in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2016; 4:490.</a></li><li><a class="nounderline abstract_t">Borlaug BA. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J 2014; 78:20.</a></li><li><a class="nounderline abstract_t">Cheng CP, Igarashi Y, Little WC. Mechanism of augmented rate of left ventricular filling during exercise. Circ Res 1992; 70:9.</a></li><li><a class="nounderline abstract_t">Cheng CP, Noda T, Nozawa T, Little WC. Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 1993; 72:795.</a></li><li class="breakAll">Little WC, Cheng CP. Modulation of diastolic dysfunction in the intact heart. In: Diastolic Relaxation of the Heart, 2nd ed, Lorell BH, Grossman W (Eds), Kluwer Academic Publishers, Boston 1994. p.167.</li><li><a class="nounderline abstract_t">Little WC. Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation. Circulation 2005; 112:2888.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 2016; 37:3293.</a></li><li><a class="nounderline abstract_t">Ohara T, Niebel CL, Stewart KC, et al. Loss of adrenergic augmentation of diastolic intra-LV pressure difference in patients with diastolic dysfunction: evaluation by color M-mode echocardiography. JACC Cardiovasc Imaging 2012; 5:861.</a></li><li><a class="nounderline abstract_t">Carroll JD, Hess OM, Hirzel HO, Krayenbuehl HP. Dynamics of left ventricular filling at rest and during exercise. Circulation 1983; 68:59.</a></li><li><a class="nounderline abstract_t">Carroll JD, Hess OM, Hirzel HO, Krayenbuehl HP. Exercise-induced ischemia: the influence of altered relaxation on early diastolic pressures. Circulation 1983; 67:521.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Jaber WA, Ommen SR, et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011; 97:964.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588.</a></li><li><a class="nounderline abstract_t">Quiñones MA, Zile MR, Massie BM, et al. Chronic heart failure: a report from the Dartmouth Diastole Discourses. Congest Heart Fail 2006; 12:162.</a></li><li><a class="nounderline abstract_t">Borbély A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005; 111:774.</a></li><li><a class="nounderline abstract_t">van Heerebeek L, Borbély A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113:1966.</a></li><li><a class="nounderline abstract_t">Persson H, Lonn E, Edner M, et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007; 49:687.</a></li><li><a class="nounderline abstract_t">Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007; 115:1982.</a></li><li><a class="nounderline abstract_t">Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007; 49:198.</a></li><li><a class="nounderline abstract_t">Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015; 131:1247.</a></li><li><a class="nounderline abstract_t">Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131:550.</a></li><li><a class="nounderline abstract_t">Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006; 47:500.</a></li><li><a class="nounderline abstract_t">Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089.</a></li><li><a class="nounderline abstract_t">Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387.</a></li><li><a class="nounderline abstract_t">Andersen MJ, Olson TP, Melenovsky V, et al. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 2015; 8:41.</a></li><li><a class="nounderline abstract_t">Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344:17.</a></li><li><a class="nounderline abstract_t">Vinch CS, Aurigemma GP, Hill JC, et al. Usefulness of clinical variables, echocardiography, and levels of brain natriuretic peptide and norepinephrine to distinguish systolic and diastolic causes of acute heart failure. Am J Cardiol 2003; 91:1140.</a></li><li><a class="nounderline abstract_t">Zile MR, Bourge RC, Bennett TD, et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail 2008; 14:816.</a></li><li><a class="nounderline abstract_t">Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118:1433.</a></li><li><a class="nounderline abstract_t">Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260.</a></li><li><a class="nounderline abstract_t">Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251.</a></li><li><a class="nounderline abstract_t">Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47:76.</a></li><li><a class="nounderline abstract_t">Brucks S, Little WC, Chao T, et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 2004; 93:1055.</a></li><li><a class="nounderline abstract_t">Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112:357.</a></li><li><a class="nounderline abstract_t">O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006; 113:986.</a></li><li><a class="nounderline abstract_t">Zile MR. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation 2005; 112:300.</a></li><li><a class="nounderline abstract_t">Katz AM, Zile MR. New molecular mechanism in diastolic heart failure. Circulation 2006; 113:1922.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Lam CS, Roger VL, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54:410.</a></li><li><a class="nounderline abstract_t">Yu CM, Lin H, Yang H, et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002; 105:1195.</a></li><li><a class="nounderline abstract_t">Yip G, Wang M, Zhang Y, et al. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart 2002; 87:121.</a></li><li><a class="nounderline abstract_t">Petrie MC, Caruana L, Berry C, McMurray JJ. "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart 2002; 87:29.</a></li><li><a class="nounderline abstract_t">Nikitin NP, Witte KK, Clark AL, Cleland JG. Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. Am J Cardiol 2002; 90:1174.</a></li><li><a class="nounderline abstract_t">Shah AM, Claggett B, Folsom AR, et al. Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation 2015; 132:1979.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56:845.</a></li><li><a class="nounderline abstract_t">Abudiab MM, Redfield MM, Melenovsky V, et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15:776.</a></li><li><a class="nounderline abstract_t">Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53:1119.</a></li><li><a class="nounderline abstract_t">Gorter TM, Hoendermis ES, van Veldhuisen DJ, et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 2016; 18:1472.</a></li><li><a class="nounderline abstract_t">Reddy YNV, Borlaug BA. Pulmonary Hypertension in Left Heart Disease. Clin Chest Med 2021; 42:39.</a></li><li><a class="nounderline abstract_t">Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377:658.</a></li><li><a class="nounderline abstract_t">Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7:935.</a></li><li><a class="nounderline abstract_t">Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309:1268.</a></li><li><a class="nounderline abstract_t">Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36:2565.</a></li><li><a class="nounderline abstract_t">Zile MR, Bourge RC, Redfield MM, et al. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail 2014; 2:123.</a></li><li><a class="nounderline abstract_t">Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3452.</a></li><li><a class="nounderline abstract_t">Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014; 130:2310.</a></li><li><a class="nounderline abstract_t">Burke MA, Katz DH, Beussink L, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2014; 7:288.</a></li><li><a class="nounderline abstract_t">Gorter TM, van Veldhuisen DJ, Bauersachs J, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20:16.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Obokata M. Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease. Eur Heart J 2017; 38:2874.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Lam CSP, Vachiery JL, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. Eur Heart J 2017; 38:2869.</a></li><li><a class="nounderline abstract_t">Obokata M, Reddy YNV, Melenovsky V, et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40:689.</a></li><li><a class="nounderline abstract_t">Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62:263.</a></li><li><a class="nounderline abstract_t">Akiyama E, Sugiyama S, Matsuzawa Y, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2012; 60:1778.</a></li><li><a class="nounderline abstract_t">Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018; 39:3439.</a></li><li><a class="nounderline abstract_t">Kato S, Saito N, Kirigaya H, et al. Impairment of Coronary Flow Reserve Evaluated by Phase Contrast Cine-Magnetic Resonance Imaging in Patients With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">Obokata M, Reddy YNV, Melenovsky V, et al. Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2018; 72:29.</a></li><li><a class="nounderline abstract_t">Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018; 39:840.</a></li><li><a class="nounderline abstract_t">Weber T, Wassertheurer S, O'Rourke MF, et al. Pulsatile hemodynamics in patients with exertional dyspnea: potentially of value in the diagnostic evaluation of suspected heart failure with preserved ejection fraction. J Am Coll Cardiol 2013; 61:1874.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Cardiol Clin 2011; 29:447.</a></li><li><a class="nounderline abstract_t">Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59:442.</a></li><li><a class="nounderline abstract_t">Reddy YNV, Andersen MJ, Obokata M, et al. Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2017; 70:136.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006; 114:2138.</a></li><li><a class="nounderline abstract_t">Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. Circulation 2011; 123:1010.</a></li><li><a class="nounderline abstract_t">Haykowsky MJ, Brubaker PH, John JM, et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 2011; 58:265.</a></li><li><a class="nounderline abstract_t">Dhakal BP, Malhotra R, Murphy RM, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail 2015; 8:286.</a></li><li><a class="nounderline abstract_t">Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol 2015; 12:294.</a></li><li><a class="nounderline abstract_t">Houstis NE, Eisman AS, Pappagianopoulos PP, et al. Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O2 Pathway Analysis. Circulation 2018; 137:148.</a></li><li><a class="nounderline abstract_t">Kitzman DW, Upadhya B, Vasu S. What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. Circulation 2015; 131:522.</a></li><li><a class="nounderline abstract_t">Haykowsky MJ, Brubaker PH, Stewart KP, et al. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol 2012; 60:120.</a></li><li><a class="nounderline abstract_t">Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013; 128:1085.</a></li><li><a class="nounderline abstract_t">Zakeri R, Borlaug BA, McNulty SE, et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 2014; 7:123.</a></li><li><a class="nounderline abstract_t">Reddy YNV, Obokata M, Verbrugge FH, et al. Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. J Am Coll Cardiol 2020; 76:1051.</a></li><li><a class="nounderline abstract_t">Melenovsky V, Hwang SJ, Redfield MM, et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 2015; 8:295.</a></li><li><a class="nounderline abstract_t">Santos AB, Roca GQ, Claggett B, et al. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2016; 9:e002763.</a></li><li><a class="nounderline abstract_t">Freed BH, Daruwalla V, Cheng JY, et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. Circ Cardiovasc Imaging 2016; 9.</a></li><li><a class="nounderline abstract_t">Reddy YNV, Obokata M, Egbe A, et al. Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. Eur J Heart Fail 2019; 21:891.</a></li><li><a class="nounderline abstract_t">Telles F, Nanayakkara S, Evans S, et al. Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction. Eur J Heart Fail 2019; 21:495.</a></li><li><a class="nounderline abstract_t">Omote K, Borlaug BA. Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction. Circ J 2023; 87:1039.</a></li><li><a class="nounderline abstract_t">Wohlfahrt P, Redfield MM, Lopez-Jimenez F, et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. JACC Heart Fail 2014; 2:489.</a></li><li><a class="nounderline abstract_t">Obokata M, Reddy YN, Pislaru SV, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction. Circulation 2017.</a></li><li><a class="nounderline abstract_t">Reddy YNV, Lewis GD, Shah SJ, et al. Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Mayo Clin Proc 2019; 94:1199.</a></li><li><a class="nounderline abstract_t">Sorimachi H, Burkhoff D, Verbrugge FH, et al. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail 2021; 23:1648.</a></li><li><a class="nounderline abstract_t">Sorimachi H, Obokata M, Takahashi N, et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. Eur Heart J 2021; 42:1595.</a></li><li><a class="nounderline abstract_t">Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 2019; 568:351.</a></li><li><a class="nounderline abstract_t">Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res 2021; 117:423.</a></li><li><a class="nounderline abstract_t">Rush CJ, Berry C, Oldroyd KG, et al. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2021; 6:1130.</a></li><li><a class="nounderline abstract_t">Mohammed SF, Majure DT, Redfield MM. Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2016; 9.</a></li><li><a class="nounderline abstract_t">van Empel VP, Mariani J, Borlaug BA, Kaye DM. Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc 2014; 3:e001293.</a></li><li><a class="nounderline abstract_t">Saiki H, Petersen IA, Scott CG, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation 2017; 135:1388.</a></li><li><a class="nounderline abstract_t">Tian R, Christe ME, Spindler M, et al. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 1997; 99:745.</a></li><li><a class="nounderline abstract_t">Cave AC, Ingwall JS, Friedrich J, et al. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 2000; 101:2090.</a></li><li><a class="nounderline abstract_t">Saupe KW, Eberli FR, Ingwall JS, Apstein CS. Metabolic support as an adjunct to inotropic support in the hypoperfused heart. J Mol Cell Cardiol 2001; 33:261.</a></li><li><a class="nounderline abstract_t">Eberli FR, Strömer H, Ferrell MA, et al. Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts. Circulation 2000; 102:2643.</a></li><li><a class="nounderline abstract_t">Steine K, Stugaard M, Smiseth OA. Mechanisms of retarded apical filling in acute ischemic left ventricular failure. Circulation 1999; 99:2048.</a></li><li><a class="nounderline abstract_t">Apstein CS, Grossman W. Opposite initial effects of supply and demand ischemia on left ventricular diastolic compliance: the ischemia-diastolic paradox. J Mol Cell Cardiol 1987; 19:119.</a></li><li><a class="nounderline abstract_t">Varma N, Eberli FR, Apstein CS. Increased diastolic chamber stiffness during demand ischemia: response to quick length change differentiates rigor-activated from calcium-activated tension. Circulation 2000; 101:2185.</a></li><li><a class="nounderline abstract_t">Varma N, Eberli FR, Apstein CS. Left ventricular diastolic dysfunction during demand ischemia: rigor underlies increased stiffness without calcium-mediated tension. Amelioration by glycolytic substrate. J Am Coll Cardiol 2001; 37:2144.</a></li><li><a class="nounderline abstract_t">Pepine CJ, Wiener L. Relationship of anginal symptoms to lung mechanics during myocardial ischemia. Circulation 1972; 46:863.</a></li><li><a class="nounderline abstract_t">McKenney PA, Apstein CS, Mendes LA, et al. Increased left ventricular diastolic chamber stiffness immediately after coronary artery bypass surgery. J Am Coll Cardiol 1994; 24:1189.</a></li><li><a class="nounderline abstract_t">McKenney PA, Apstein CS, Mendes LA, et al. Immediate effect of aortic valve replacement for aortic stenosis on left ventricular diastolic chamber stiffness. Am J Cardiol 1999; 84:914.</a></li><li><a class="nounderline abstract_t">Bolli R. Myocardial 'stunning' in man. Circulation 1992; 86:1671.</a></li></ol></div><div id="topicVersionRevision">Topic 3457 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120821" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Heart Failure With Preserved Ejection Fraction In Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959663" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heart Failure with Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418449" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502702" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742292" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Heart failure with preserved ejection fraction: is this diastolic heart failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356307" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical practice. Diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128895" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851588" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555723" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206819" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28455343" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958077" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The pathophysiology of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26374849" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26530107" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Defining HFpEF: where do we draw the line?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506115" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152557" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of heart failure with normal ejection fraction: an inconvenient truth!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892060" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27358439" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21138935" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21129719" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715358" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24768876" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Implications of coronary artery disease in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003645" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diastolic heart failure: definitions and terminology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23811963" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Longitudinal changes in left ventricular stiffness: a community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808325" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of left ventricular diastolic dysfunction in a general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21862747" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Progression of left ventricular diastolic dysfunction and risk of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27256752" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impaired Pulmonary Diffusion in Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24305634" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mechanisms of exercise intolerance in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1345778" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mechanism of augmented rate of left ventricular filling during exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095187" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095187" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275877" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354047" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22974796" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Loss of adrenergic augmentation of diastolic intra-LV pressure difference in patients with diastolic dysfunction: evaluation by color M-mode echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6851055" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dynamics of left ventricular filling at rest and during exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6821894" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Exercise-induced ischemia: the influence of altered relaxation on early diastolic pressures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21478380" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543134" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760702" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronic heart failure: a report from the Dartmouth Diastole Discourses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699264" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiomyocyte stiffness in diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16618817" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Myocardial structure and function differ in systolic and diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291934" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404159" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222731" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25552356" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458127" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636176" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11901053" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25342738" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136955" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The pathogenesis of acute pulmonary edema associated with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714167" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Usefulness of clinical variables, echocardiography, and levels of brain natriuretic peptide and norepinephrine to distinguish systolic and diastolic causes of acute heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041044" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794390" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855266" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcome of heart failure with preserved ejection fraction in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855265" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Trends in prevalence and outcome of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386668" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15081458" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Relation of anemia to diastolic heart failure and the effect on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009792" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476847" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027268" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636184" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : New molecular mechanism in diastolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628115" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889013" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796546" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11751660" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423730" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26350059" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813282" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426022" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324256" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27650220" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33541616" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pulmonary Hypertension in Left Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21315441" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25286913" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23478662" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26188003" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24720918" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875795" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Right heart dysfunction in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25391518" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Right ventricular function in heart failure with preserved ejection fraction: a community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365774" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29044932" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28431020" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011705" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30544228" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684677" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040568" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165580" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908404" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impairment of Coronary Flow Reserve Evaluated by Phase Contrast Cine-Magnetic Resonance Imaging in Patients With Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29957229" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29293969" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23500307" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pulsatile hemodynamics in patients with exertional dyspnea: potentially of value in the diagnostic evaluation of suspected heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21803232" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ventricular-vascular interaction in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281246" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28683960" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088459" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21382903" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Chronotropic incompetence: causes, consequences, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737017" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25344549" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26089855" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993402" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O2 Pathway Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25552355" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766338" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23908348" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162898" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32854840" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25593126" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056882" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26941415" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30919562" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30652393" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34645733" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25194285" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Impact of general and central adiposity on ventricular-arterial aging in women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28381470" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31272568" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34053158" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33227126" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30971818" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Nitrosative stress drives heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32666082" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Metabolic inflammation in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160566" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27413038" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25468660" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28132957" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9045879" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10790352" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11162131" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Metabolic support as an adjunct to inotropic support in the hypoperfused heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085969" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209011" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Mechanisms of retarded apical filling in acute ischemic left ventricular failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3550105" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Opposite initial effects of supply and demand ischemia on left ventricular diastolic compliance: the ischemia-diastolic paradox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10801760" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Increased diastolic chamber stiffness during demand ischemia: response to quick length change differentiates rigor-activated from calcium-activated tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419901" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Left ventricular diastolic dysfunction during demand ischemia: rigor underlies increased stiffness without calcium-mediated tension. Amelioration by glycolytic substrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4628188" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Relationship of anginal symptoms to lung mechanics during myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930238" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Increased left ventricular diastolic chamber stiffness immediately after coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10532510" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Immediate effect of aortic valve replacement for aortic stenosis on left ventricular diastolic chamber stiffness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451239" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Myocardial 'stunning' in man.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
